0001562180-24-000637.txt : 20240125 0001562180-24-000637.hdr.sgml : 20240125 20240125182621 ACCESSION NUMBER: 0001562180-24-000637 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240123 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paggiarino Dario A. CENTRAL INDEX KEY: 0001574261 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 24563517 MAIL ADDRESS: STREET 1: 4025 SORRENTO VALLEY BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-01-23 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001574261 Paggiarino Dario A. C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 false true false false Chief Medical Officer false Common Stock 2024-01-23 4 M false 3096.00 13.13 A 39601.00 D Common Stock 2024-01-23 4 M false 2039.00 12.90 A 41640.00 D Common Stock 2024-01-23 4 S false 2039.00 25.00 D 39601.00 D Common Stock 2024-01-23 4 S false 3096.00 25.00 D 36505.00 D Common Stock 2024-01-24 4 M false 5651.00 12.90 A 42156.00 D Common Stock 2024-01-24 4 M false 5600.00 13.13 A 47756.00 D Common Stock 2024-01-24 4 S false 5600.00 25.0093 D 42156.00 D Common Stock 2024-01-24 4 S false 5651.00 25.0156 D 36505.00 D Stock Option (Right to Buy) 13.13 2024-01-23 4 M false 3096.00 0.00 D 2031-02-09 Common Stock 3096.00 57204.00 D Stock Option (Right to Buy) 12.90 2024-01-23 4 M false 2039.00 0.00 D 2030-02-28 Common Stock 2039.00 22586.00 D Stock Option (Right to Buy) 13.13 2024-01-24 4 M false 5600.00 0.00 D 2031-02-09 Common Stock 5600.00 51604.00 D Stock Option (Right to Buy) 12.90 2024-01-24 4 M false 5651.00 0.00 D 2030-02-28 Common Stock 5651.00 16935.00 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.14. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2021 and the remainder ratably, on a monthly basis, over the remaining three years. The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 /s/ Ron Honig, Attorney-in-Fact 2024-01-25